Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is experiencing positive momentum due to significant advancements in its intellectual property portfolio, particularly a patent set to expire in 2039, which enhances its competitive edge in the aesthetics market. The partnership with AbbVie has already generated $24 million of potential $50 million in milestone payments, highlighting the commercial viability and growing confidence in CollPlant’s rhCollagen technology. Additionally, strategic cost optimization initiatives are underway to extend the company’s financial runway as it progresses toward human trials, further solidifying its long-term growth prospects in the regenerative medicine and aesthetics sectors.

Bears say

CollPlant Biotechnologies Ltd faces challenges highlighted by its dependence on strategic collaborations and a niche market that may limit revenue growth potential, especially amid fierce competition in the regenerative medicine sector. The company's reliance on multiple revenue streams from its BioInk sales and rhCollagen products may not be sufficient to offset risks associated with market fluctuations and regulatory hurdles. Additionally, the geographic concentration of revenues and the potential for limited market penetration in key regions further suggest vulnerabilities that could impact overall financial stability.

CLGN has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 4 analysts, CLGN has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.